Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: Results of a phase II clinical trial

Asher Chanan-Khan, Kena C. Miller, Laurie Musial, Swaminathan Padmanabhan, Jihnhee Yu, Sikander Ailawadhi, Taimur Sher, Alice Mohr, Zale P. Bernstein, Maurice Barcos, Mehul Patel, Dan Iancu, Kelvin Lee, Myron S. Czuczman

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone. The steroid doses employed in myeloma regimens are often poorly tolerated. Therefore, in a phase II clinical trial we investigated the efficacy of a steroid-free combination including bortezomib, pegylated liposomal doxorubicin and thalidomide (VDT regimen). Twenty-three patients with relapsed or refractory myeloma or other plasma cell cancers were treated with the VDT regimen. Patient had a median of five prior therapies and 65.2% were refractory to their last regimen. The overall response rates were 55.5% and 22%, respectively. The median progression free survival was 10.9 months (95% CI: 7.3-15.8) and the median overall survival was 15.7 months (95% CI: 9.1-not reached). Fatigue and sensory neuropathy were the most common side effects noted. We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma.

Original languageEnglish (US)
Pages (from-to)1096-1101
Number of pages6
JournalLeukemia and Lymphoma
Volume50
Issue number7
DOIs
StatePublished - 2009

Keywords

  • Bortezomib
  • Doxil
  • Multiple myeloma
  • Non-steroidal
  • Relapsed/refractory

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: Results of a phase II clinical trial'. Together they form a unique fingerprint.

Cite this